Table 1.
Patient-, Cancer-, and Treatment-Specific Characteristics
| Characteristic | IMRT (n=204) | PT (n=1243) | P-Value |
|---|---|---|---|
| Median Age in Years (range) | 69 (46 - 84) | 66 (40 - >89) | <0.001 |
| Mean Body-mass Index (SD) | 28.6 (5.5) | 28.2 (4.3) | 0.64 |
| Mean Prostate Size in ml (SD) | 49.5 (27.2) | 41.5 (20.7) | 0.001 |
| No. of Patients (%) | No. of Patients (%) | ||
| Race | <0.001 | ||
| White | 166 (81%) | 1132 (91%) | |
| Black | 34 (17%) | 77 (6%) | |
| Other | 4 (2%) | 34 (3%) | |
| PSA | 0.12 | ||
| <4 ng/ml | 37 (17%) | 205 (17%) | |
| 4-10 ng/ml | 128 (63%) | 862 (69%) | |
| >10 ng/ml | 39 (19%) | 176 (14%) | |
| Gleason Score | 0.28 | ||
| <7 | 104 (51%) | 659 (53%) | |
| 7 | 86 (42%) | 466 (37%) | |
| >7 | 14 (7%) | 118 (10%) | |
| Clinical Stagea | 0.61 | ||
| T1 | 148 (73%) | 922 (74%) | |
| T2 | 56 (27%) | 317 (26%) | |
| T3 | 0 (0%) | 3 (<1%) | |
| Overall Risk level | 0.41 | ||
| Low | 83 (41%) | 567 (46%) | |
| Intermediate | 94 (46%) | 532 (43%) | |
| High | 27 (13%) | 143 (11%) | |
| ADT | 49 (24%) | 181 (15%) | 0.001 |
| Median PTV min (range) | 70.9 (40.7 - 90.2) | 74.1 (40.0 - 80.7) | <0.001 |
| Median PTVmax (range) | 81.5 (45.0 - 107.0) | 83.2 (60.5 - 93.3) | <0.001 |
PSA, prostate-specific antigen; IMRT, intensity modulated radiotherapy; PT, proton therapy; ADT, androgen deprivation therapy; PTV, planned target volume; SD, standard deviation
a
One proton therapy patient had no T stage